Stay updated with breaking news from Denis Bedoret. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DGAP-News: Imcyse SA / Key word(s): Study 13.04.2022 / 13:00 The issuer is solely responsible for the content of this announcement. Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis IMCY-MS-001 study aims to determine safe...
DGAP-News: Imcyse SA / Key word(s): Conference Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference 14.03.2022 / 12:00 The issuer is solely responsible for the content of this announcement. Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference Liège, Belgium, March 14,...
13.01.2022 Imcyse SA: Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study | Imcyse SA | News | Nachricht | Mitteilung
DGAP-News: Imcyse SA / Key word(s): Personnel Imcyse Appoints Gene Mack, MBA as Chief Financial Officer 03.11.2021 / 13:00 The issuer is solely responsible for the content of this announcement. Imcyse Appoints Gene Mack, MBA as Chief Financial Officer Liège, Belgium, November 3, 2021 - Imcyse, a...
5 (3) Imcyse has raised €21.3 million ($25.8 million) in funding to advance its innovative immunotherapy platform for the treatment of multiple sclerosis (MS) and other severe autoimmune diseases. The funding was a result of a series B financing round featuring existing investors such as Biogenosis, Société Fédérale de Participations et d’Investissement, and the Catholic University of Leuven, as well as the newest investor Pfizer, which took an equity stake as part of a previously announced licensing agreement. “Completing this financing round reinforces the st...